Back to Peptide Encyclopedia
Weight Loss & MetabolicApproved
Liraglutide
Saxenda / Victoza
First-generation GLP-1 agonist, approved for obesity and type 2 diabetes.
Prescription2 protocols
FDA & EMA approved — for specific indications
·Educational information. Not medical advice or a recommendation for use.Key Facts: Liraglutide
Category
Weight Loss & Metabolic
Evidence
Approved
Availability
Prescription
Protocols
2
Research Overview & Mechanisms
GLP-1 receptor activation with daily administration.
Reported Research Benefits
Weight loss
Glycemic control
Available Protocols
Frequently Asked Questions
FAQ
First-generation GLP-1 agonist, approved for obesity and type 2 diabetes.
Advanced Compound Intelligence
—
Human studies
—
Key studies
—
Interactions
Approved
Evidence tier
Verified intelligence
Research summaryClinical Evidence
Approved
View all studies on PubMedApproved by regulatory agencies (FDA/EMA) with extensive Phase III clinical trial data.
Scientific Sources & Further Reading
Explore peer-reviewed research about Liraglutide:
External links open in new tabs. Always verify information with qualified healthcare providers.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →